FindTrial
Sign In

Liposomal Annamycin

DRUG9 trials

Sponsors

Moleculin Biotech Inc., Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy, NYU Langone Health, Callisto Pharmaceuticals, Moleculin Biotech, Inc.

Conditions

Acute Lymphocytic LeukemiaAcute Myelogenous LeukemiaAcute Myeloid LeukemiaBreast CancerLeukemia, Myeloid, AcuteMETASTATIC SOFT-TISSUE SARCOMAS AFTER FAILURE ON AT LEAST ONE SYSTEMIC THERAPY

Phase 1

Chemotherapy in Treating Patients With Breast Cancer
CompletedNCT00012129
NYU Langone HealthBreast Cancer
Start: 1998-09-30Updated: 2016-03-11
Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia
NCT00271063
Callisto PharmaceuticalsAcute Lymphocytic Leukemia
Start: 2005-10-31End: 2008-04-30Target: 34Updated: 2007-12-21
Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML
TerminatedNCT00430443
Callisto PharmaceuticalsAcute Lymphocytic Leukemia, Acute Myelogenous Leukemia
Start: 2007-02-28End: 2009-01-31Updated: 2011-08-31
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
CompletedNCT03315039
Moleculin Biotech, Inc.Leukemia, Myeloid, Acute
Start: 2018-03-28End: 2020-06-20Updated: 2022-03-10
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
CompletedNCT03388749
Moleculin Biotech, Inc.Leukemia, Myeloid, Acute
Start: 2018-12-17End: 2022-02-14Updated: 2023-01-20
Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
CompletedNCT05319587
Moleculin Biotech, Inc.Leukemia, Myeloid, Acute
Start: 2022-09-29End: 2023-08-10Updated: 2025-09-30
Phase 1/2 Study of Liposomal Annamycin in Combination with Cytarabine for the Treatment of Subjects with Acute Myeloid Leukemia (AML).
CompletedCTIS2024-516388-10-00
Moleculin Biotech Inc.Acute Myeloid Leukemia
Start: 2022-09-23End: 2025-08-26Target: 24Updated: 2025-08-29
Phase 1b/2 study of liposomal annamycin (l-annamycin) in patients with previously treated metastatic soft-tissue sarcomas (ANNA-SARC)
CompletedCTIS2024-517678-12-00
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut BadawczyMETASTATIC SOFT-TISSUE SARCOMAS AFTER FAILURE ON AT LEAST ONE SYSTEMIC THERAPY
Start: 2021-01-14End: 2025-03-31Target: 30Updated: 2025-01-11

Phase 2

A Pivotal Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of L Annamycin for Injection in Combination with Cytarabine Injection Versus Placebo in Combination with Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects with Refractory/Relapsed Acute Myeloid Leukemia
RecruitingCTIS2024-518359-47-00
Moleculin Biotech Inc.Acute Myeloid Leukemia
Start: 2025-06-17Target: 177Updated: 2025-12-10

Related Papers

Annamycin, a Non-Cardiotoxic Anthracycline Demonstrates Unique Organotropism and Activity Against Ara-C and Venetoclax Resistant AML
Blood2024-11-05
Abstract LB180: Non-cardiotoxic properties of annamycin, a clinically evaluated anthracycline and potent topoisomerase 2β poison
Cancer Research2024-04-05
Preliminary Results from a Phase 1/2 Study of Liposomal Annamycin (L-ANN) in Combination with Cytarabin for the Treatment of Patients with Acute Myeloid Leukemia (AML) That Is Refractory to or Relapsed (r/r) after Induction Therapy
Blood2023-11-022 citations